Body Space or Junction

Novo Nordisk’s Wegovy Pill Launches Strongly Amid Analyst Caution

1 day ago talkbio0Tagged Approved, Eli, Glucagon-Like Peptide 1, Novo Nordisk, Obesity Drug, Oral cavity, United States Food and Drug Administration, Wegovy pill

Wegovy pill; Novo Nordisk; FDA approval; oral GLP-1; obesity drug; Eli Lilly competition

Novo Nordisk Launches Wegovy Pill in the US with Broad Availability

3 weeks ago talkbio0Tagged Glucagon-Like Peptide 1, January 2026, Novo Nordisk, Oral cavity, U.S., Wegovy pill, Weight Loss

Novo Nordisk; Wegovy pill; US launch; January 2026; oral GLP-1; weight loss

Lilly seeks rapid FDA approval for oral GLP-1 orforglipron after positive obesity “switching” study

1 month ago talkbio0Tagged Approved, Clinical Trials, Eli, Glucagon-Like Peptide 1, injectable incretins, national priority review voucher, Obesity, Oral cavity, orforglipron, Phase 3 trial, United States Food and Drug Administration, Wegovy, weight maintenance, Zepbound

Eli Lilly; orforglipron; oral GLP-1; FDA approval; national priority review voucher; ATTAIN-MAINTAIN trial; obesity treatment; weight maintenance; Zepbound; Wegovy; injectable incretins; Phase 3 trial

Insilico Medicine and TaiGen sign exclusive licensing deal for AI-designed PHD inhibitor ISM4808 to treat anemia in chronic kidney disease

1 month ago talkbio0Tagged AI-driven, Anemia, CDE, China, Chronic Kidney Diseases, Clearance, clinical-stage biotech, Drug Discovery, Generative AI, Indonesian language, Insilico Medicine, ISM4808, License Agreement, Oral cavity, Ph.D., Pharma, PHD inhibitor, TaiGen Biotechnology

Insilico Medicine; TaiGen Biotechnology; license agreement; ISM4808; PHD inhibitor; anemia of Chronic Kidney Disease; CKD anemia; AI-driven drug discovery; Pharma.AI; Greater China rights; oral PHD inhibitor; IND clearance; China CDE; generative AI; clinical-stage biotech

Kymera’s oral “Dupixent-in-a-pill” KT-621 shows strong early eczema results

2 months ago talkbio0Tagged BroADen Phase 1b trial, Clinical, Dermatitis, Atopic, Dupixent, Dupixent-in-a-pill, Eczema, KT-621, Kymera Therapeutics, Oral cavity, STAT6 degrader, type 2 inflammation

Kymera Therapeutics; KT-621; Dupixent-in-a-pill; oral STAT6 degrader; atopic dermatitis; eczema; BroADen Phase 1b trial; Dupixent rival; Type 2 inflammation; early clinical data

Structure Therapeutics’ oral obesity drug shows competitive early data vs Novo and Lilly; Ascletis reports early obesity results

2 months ago talkbio0Tagged ASC41, Ascletis, eli lilly, Glucagon-Like Peptide 1, GSBR-1290, Obesity, Oral cavity, Ozempic, Phase 2 trial, safety profile, Structure Therapeutics, Wegovy, Weight Loss, Weight-Loss Agents, Zepbound

Structure Therapeutics; GSBR-1290; oral GLP-1; obesity pill; weight-loss drug; Novo Nordisk; Eli Lilly; Wegovy; Ozempic; Zepbound; Ascletis; ASC41; ASC42; phase 1 trial; phase 2 trial; weight reduction; safety profile

Jesper Høiland Joins Alva Therapeutics’ Board of Directors

2 months ago talkbio0Tagged Alva Therapeutics, board of directors, Clinical Development, Diabetes Mellitus, Non-Insulin-Dependent, incretin secretagogue, Novo Nordisk, Obesity, Oral cavity, pharmaceutical commercialization

Alva Therapeutics; Board of Directors; Novo Nordisk; Type 2 diabetes; obesity; oral incretin secretagogue; clinical development; pharmaceutical commercialization

Jesper Høiland Joins Alva Therapeutics’ Board of Directors

2 months ago talkbio0Tagged Alva Therapeutics, board of directors, Clinical Development, Diabetes Mellitus, Non-Insulin-Dependent, incretin secretagogue, Novo Nordisk, Obesity, Oral cavity, pharmaceutical commercialization

Alva Therapeutics; Board of Directors; Novo Nordisk; Type 2 diabetes; obesity; oral incretin secretagogue; clinical development; pharmaceutical commercialization

Halda’s HLD-0915 Shows Promising First-in-Human Results as a Safer RIPTAC Cancer Therapeutic

3 months ago talkbio0Tagged anti-tumor activity, first-in-human, Halda Therapeutics, HLD-0915, Metastatic castration-resistant prostate cancer, Oral cavity, RIPTAC, Safety

Halda Therapeutics; HLD-0915; RIPTAC; metastatic castration-resistant prostate cancer; first-in-human; safety; anti-tumor activity; oral therapeutic

Rani Therapeutics Appoints Abe Bassan and Vasudev Bailey to Board of Directors

3 months ago talkbio0Tagged Abe Bassan, Anomaly Ventures, BioCapital, Biological Factors, biotherapeutics, Board change, board of directors, Chugai, Collaboration, Obstetric Delivery, Oral cavity, Rani Therapeutics, Samsara, Vasudev Bailey

Rani Therapeutics; Board of Directors; Abe Bassan; Vasudev Bailey; biotherapeutics; oral biologics delivery; Samsara BioCapital; Anomaly Ventures; Chugai collaboration; Board change